Revolutionary Therapy Restores Life for René, 57: “I’ve Shaken Since Childhood”

A revolutionary deep brain stimulation (DBS) therapy has significantly improved the quality of life for a 57-year-old Dutch man who has lived with severe essential tremor since childhood, according to a report by De Telegraaf.

René, whose full name was not disclosed in the report, described a lifelong struggle with involuntary shaking that began in early childhood and worsened over decades, affecting basic tasks such as holding a cup, writing, or eating independently. Despite trying various medications, he found little relief until undergoing a specialized DBS procedure targeting the ventral intermediate nucleus of the thalamus, a brain region involved in motor control.

The treatment, performed at a specialized neurological center in the Netherlands, involved implanting electrodes deep within the brain to deliver regulated electrical pulses that modulate abnormal neural activity responsible for tremor. Following the surgery and subsequent device calibration, René reported a dramatic reduction in tremors, allowing him to regain control over movements that had been impaired for over five decades.

“From as long as I can remember, I shook,” René said in the interview with De Telegraaf. “It was part of me — but now, for the first time, I can hold my grandson’s hand without it trembling.”

Understanding Essential Tremor and the Role of DBS

Essential tremor is one of the most common movement disorders, affecting an estimated 1% of the global population and rising to 4–5% among those over age 65, according to the International Essential Tremor Foundation. We see characterized by rhythmic, involuntary shaking, most commonly in the hands, but can also affect the head, voice, legs, or trunk. Unlike Parkinson’s disease tremor, essential tremor typically occurs during action — such as reaching for an object — rather than at rest.

While the exact cause remains unknown, research suggests a combination of genetic predisposition and abnormal signaling in circuits involving the cerebellum and thalamus. First-line treatments include medications such as propranolol and primidone, but up to 30–50% of patients do not achieve adequate symptom control or experience intolerable side effects.

For medication-resistant cases, DBS has emerged as a well-established surgical option. Approved by the U.S. Food and Drug Administration (FDA) for essential tremor in 1997, DBS does not destroy brain tissue but instead regulates dysfunctional neural pathways. The procedure is reversible and adjustable, allowing clinicians to fine-tune stimulation parameters over time to optimize outcomes.

Evidence Supporting DBS for Essential Tremor

Clinical studies have consistently shown that DBS can reduce tremor severity by 50–90% in the contralateral limbs, with sustained benefits observed over multiple years. A 2021 meta-analysis published in JAMA Neurology reviewed data from over 1,000 patients and concluded that DBS provides superior tremor control compared to best medical therapy, with meaningful improvements in activities of daily living and quality of life.

Targeting the ventral intermediate nucleus (Vim) of the thalamus remains the most common and effective approach for tremor suppression. More recent research has explored dual-target or directional lead designs to improve precision and reduce side effects such as speech disturbances or gait imbalance, though Vim DBS continues to be the gold standard for many patients.

Considerations and Ongoing Care

While DBS offers substantial benefits, it is not without risks. Potential complications include surgical risks such as bleeding or infection, hardware-related issues like lead migration or device failure and stimulation-induced side effects such as numbness, tingling, or speech changes. These risks are generally low when the procedure is performed by experienced teams in specialized centers.

Long-term management requires regular follow-up to monitor battery life (typically 3–5 years for non-rechargeable devices), adjust stimulation settings, and assess neurological function. Patients are advised to undergo thorough preoperative evaluation, including neuropsychological screening, to ensure they are suitable candidates.

René’s case underscores the transformative potential of DBS for individuals with debilitating, treatment-resistant essential tremor. His experience aligns with growing clinical evidence that, for appropriately selected patients, neurostimulation can restore functional independence and improve emotional well-being after years of disability.

As access to DBS expands and technology advances — including rechargeable systems and image-guided implantation — experts anticipate broader application for movement disorders, provided that careful patient selection and multidisciplinary oversight remain central to care.